TWI708604B - 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 - Google Patents

用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 Download PDF

Info

Publication number
TWI708604B
TWI708604B TW106103338A TW106103338A TWI708604B TW I708604 B TWI708604 B TW I708604B TW 106103338 A TW106103338 A TW 106103338A TW 106103338 A TW106103338 A TW 106103338A TW I708604 B TWI708604 B TW I708604B
Authority
TW
Taiwan
Prior art keywords
skin
imidazol
tetrahydro
quinoline
ylmethyl
Prior art date
Application number
TW106103338A
Other languages
English (en)
Chinese (zh)
Other versions
TW201713338A (zh
Inventor
I 迪巴斯墨漢美德
C 夏愛德華
E 東尼歐約翰
W 吉爾丹尼爾
Original Assignee
美商歐樂根公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI708604(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商歐樂根公司 filed Critical 美商歐樂根公司
Publication of TW201713338A publication Critical patent/TW201713338A/zh
Application granted granted Critical
Publication of TWI708604B publication Critical patent/TWI708604B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
TW106103338A 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物 TWI708604B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
US61/558,104 2011-11-10

Publications (2)

Publication Number Publication Date
TW201713338A TW201713338A (zh) 2017-04-16
TWI708604B true TWI708604B (zh) 2020-11-01

Family

ID=47178364

Family Applications (3)

Application Number Title Priority Date Filing Date
TW106103338A TWI708604B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
TW108123351A TW202014189A (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
TW101141967A TWI580424B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含７－（１ｈ－咪唑－４－基甲基）－５，６，７，８－四氫－喹啉之醫藥組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW108123351A TW202014189A (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
TW101141967A TWI580424B (zh) 2011-11-10 2012-11-09 用於治療皮膚疾病及病狀之包含７－（１ｈ－咪唑－４－基甲基）－５，６，７，８－四氫－喹啉之醫藥組合物

Country Status (22)

Country Link
US (4) US20130123303A1 (cg-RX-API-DMAC7.html)
EP (3) EP2776034B1 (cg-RX-API-DMAC7.html)
JP (2) JP6359456B2 (cg-RX-API-DMAC7.html)
KR (1) KR102004563B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136029A (cg-RX-API-DMAC7.html)
AR (1) AR088845A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012335803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011336A2 (cg-RX-API-DMAC7.html)
CA (1) CA2855005C (cg-RX-API-DMAC7.html)
CL (1) CL2014001242A1 (cg-RX-API-DMAC7.html)
DK (1) DK2776034T3 (cg-RX-API-DMAC7.html)
ES (1) ES2635421T3 (cg-RX-API-DMAC7.html)
IL (3) IL232483B (cg-RX-API-DMAC7.html)
MX (1) MX350662B (cg-RX-API-DMAC7.html)
MY (1) MY182553A (cg-RX-API-DMAC7.html)
PH (1) PH12014501051A1 (cg-RX-API-DMAC7.html)
RU (2) RU2630978C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201402246RA (cg-RX-API-DMAC7.html)
TW (3) TWI708604B (cg-RX-API-DMAC7.html)
UA (1) UA109359C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013070861A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403396B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ES2765264T3 (es) * 2013-05-06 2020-06-08 Allergan Inc Agonistas alfa-adrenérgicos para el tratamiento de traumatismo tisular
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1676579T3 (da) * 1998-05-08 2009-03-16 Univ Miami Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP4975440B2 (ja) * 2003-11-20 2012-07-11 オセラ・ホールディング・インコーポレイテッド 黄斑変性およびその他の眼科疾患の改善
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792649A1 (en) * 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
KR20170018974A (ko) * 2010-03-26 2017-02-20 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
KR20130128375A (ko) * 2010-08-06 2013-11-26 갈데르마 리서치 & 디벨로프먼트 피부 질환을 치료 또는 예방하기 위한 화합물들의 배합물

Also Published As

Publication number Publication date
TW202014189A (zh) 2020-04-16
WO2013070861A1 (en) 2013-05-16
MY182553A (en) 2021-01-25
KR102004563B1 (ko) 2019-07-26
JP2017149767A (ja) 2017-08-31
RU2630978C2 (ru) 2017-09-15
SG10201609145PA (en) 2016-12-29
TW201713338A (zh) 2017-04-16
CL2014001242A1 (es) 2014-11-14
TW201328694A (zh) 2013-07-16
US20150231128A1 (en) 2015-08-20
JP6359456B2 (ja) 2018-07-18
EP2776034A1 (en) 2014-09-17
ZA201403396B (en) 2015-07-29
CA2855005C (en) 2016-11-22
AU2012335803B2 (en) 2016-05-26
US20170095466A1 (en) 2017-04-06
DK2776034T3 (en) 2017-07-10
RU2667645C1 (ru) 2018-09-21
US20160051534A1 (en) 2016-02-25
JP2014533271A (ja) 2014-12-11
AU2016216627A1 (en) 2016-09-08
IL232483A0 (en) 2014-06-30
EP3763370A1 (en) 2021-01-13
IL261269A (en) 2018-10-31
AR088845A1 (es) 2014-07-10
MX350662B (es) 2017-09-13
CA2855005A1 (en) 2013-05-16
EP2776034B1 (en) 2017-03-22
NZ624771A (en) 2016-11-25
US20130123303A1 (en) 2013-05-16
EP3184110B1 (en) 2020-10-07
BR112014011336A2 (pt) 2017-05-02
RU2014122758A (ru) 2015-12-20
TWI580424B (zh) 2017-05-01
SG10201809506TA (en) 2018-11-29
MX2014005640A (es) 2014-09-22
SG11201402246RA (en) 2014-06-27
US9308201B2 (en) 2016-04-12
PH12014501051A1 (en) 2022-11-02
KR20140107237A (ko) 2014-09-04
AU2016216627B2 (en) 2017-10-19
AU2012335803A1 (en) 2014-05-29
ES2635421T3 (es) 2017-10-03
JP6526737B2 (ja) 2019-06-05
IL268757A (en) 2019-10-31
EP3184110A1 (en) 2017-06-28
CN104136029A (zh) 2014-11-05
IL232483B (en) 2018-10-31
UA109359C2 (xx) 2015-08-10

Similar Documents

Publication Publication Date Title
TWI708604B (zh) 用於治療皮膚疾病及病狀之包含7-(1h-咪唑-4-基甲基)-5,6,7,8-四氫-喹啉之醫藥組合物
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
JP2014521644A (ja) 皮膚疾患の治療のための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンズイミダゾール−５−アミンを含む薬学的組成物
NZ624771B2 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees